Latest News
Kodiak Sciences Inc.
- Kodiak Sciences More Than Doubles on Eye Disease Trial Results
- Kodiak Sciences Up 150% At Opening Bell After Drugs Pass Key Trial
- Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3
- Kodiak skyrockets on positive study data for 2 eye drugs
- Kodiak Sciences stock hits 52-week high at 61.28 USD By Investing.com
- Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial
- Phase III Success Pushes Kodiak’s Eye Treatment Towards Approval
- Kodiak Sciences KOD Stock Soars Toward $100 After Strong Phase 3 DAYBREAK Trial Data
- Kodiak Stock Gains 183% as New Eye Drugs Take Aim at Regeneron’s Eylea
- Kodiak Sciences: Zenkuda and tabirafusp-ted meet primary endpoints in Phase 3 DAYBREAK
- Why Kodiak Sciences Skyrocketed Today
- Kodiak Sciences to Report DAYBREAK Phase 3 Results for Zenkuda and KSI-501
Headlines from the last 30 days, linking to the original publishers. See all market news →